HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $15 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.2%

Neg 0% Neu 91.2% Pos 0%

HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $15 price target.